These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 11058121)

  • 1. Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers.
    Yoo H; Juliano RL
    Nucleic Acids Res; 2000 Nov; 28(21):4225-31. PubMed ID: 11058121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAMAM dendrimers as delivery agents for antisense oligonucleotides.
    Yoo H; Sazani P; Juliano RL
    Pharm Res; 1999 Dec; 16(12):1799-804. PubMed ID: 10644065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides.
    Kang H; DeLong R; Fisher MH; Juliano RL
    Pharm Res; 2005 Dec; 22(12):2099-106. PubMed ID: 16184444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrinsically fluorescent PAMAM dendrimer as gene carrier and nanoprobe for nucleic acids delivery: bioimaging and transfection study.
    Tsai YJ; Hu CC; Chu CC; Imae T
    Biomacromolecules; 2011 Dec; 12(12):4283-90. PubMed ID: 22029823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers.
    Bielinska A; Kukowska-Latallo JF; Johnson J; Tomalia DA; Baker JR
    Nucleic Acids Res; 1996 Jun; 24(11):2176-82. PubMed ID: 8668551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic alpha,epsilon-poly(L-lysine)s as delivery agents for antisense oligonucleotides.
    Eom KD; Park SM; Tran HD; Kim MS; Yu RN; Yoo H
    Pharm Res; 2007 Aug; 24(8):1581-9. PubMed ID: 17373579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex.
    Patri AK; Kukowska-Latallo JF; Baker JR
    Adv Drug Deliv Rev; 2005 Dec; 57(15):2203-14. PubMed ID: 16290254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport.
    Hong S; Bielinska AU; Mecke A; Keszler B; Beals JL; Shi X; Balogh L; Orr BG; Baker JR; Banaszak Holl MM
    Bioconjug Chem; 2004; 15(4):774-82. PubMed ID: 15264864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the endocytic properties of linear and branched PEIs, and cationic PAMAM dendrimers in B16f10 melanoma cells.
    Seib FP; Jones AT; Duncan R
    J Control Release; 2007 Feb; 117(3):291-300. PubMed ID: 17210200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of generation 2 and 3 poly(propylenimine) dendrimers for the potential cellular delivery of antisense oligonucleotides targeting the epidermal growth factor receptor.
    Hollins AJ; Benboubetra M; Omidi Y; Zinselmeyer BH; Schatzlein AG; Uchegbu IF; Akhtar S
    Pharm Res; 2004 Mar; 21(3):458-66. PubMed ID: 15070097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of generations 2, 3 and 4 arginine modified PAMAM dendrimers for gene delivery.
    Nam HY; Hahn HJ; Nam K; Choi WH; Jeong Y; Kim DE; Park JS
    Int J Pharm; 2008 Nov; 363(1-2):199-205. PubMed ID: 18718514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disulfide cross-linked low generation dendrimers with high gene transfection efficacy, low cytotoxicity, and low cost.
    Liu H; Wang H; Yang W; Cheng Y
    J Am Chem Soc; 2012 Oct; 134(42):17680-7. PubMed ID: 23050493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendrimer-Enabled Therapeutic Antisense Delivery Systems as Innovation in Medicine.
    Mignani S; Shi X; Zablocka M; Majoral JP
    Bioconjug Chem; 2019 Jul; 30(7):1938-1950. PubMed ID: 31246431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uptake, efflux, and mass transfer coefficient of fluorescent PAMAM dendrimers into pancreatic cancer cells.
    Opitz AW; Czymmek KJ; Wickstrom E; Wagner NJ
    Biochim Biophys Acta; 2013 Feb; 1828(2):294-301. PubMed ID: 23022133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surface modification of PAMAM dendrimers modulates the mechanism of cellular internalization.
    Saovapakhiran A; D'Emanuele A; Attwood D; Penny J
    Bioconjug Chem; 2009 Apr; 20(4):693-701. PubMed ID: 19271737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
    Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
    J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro gene delivery using polyamidoamine dendrimers with a trimesyl core.
    Zhang XQ; Wang XL; Huang SW; Zhuo RX; Liu ZL; Mao HQ; Leong KW
    Biomacromolecules; 2005; 6(1):341-50. PubMed ID: 15638538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs.
    Sazani P; Kang SH; Maier MA; Wei C; Dillman J; Summerton J; Manoharan M; Kole R
    Nucleic Acids Res; 2001 Oct; 29(19):3965-74. PubMed ID: 11574678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Tat-Conjugated Dendrimer for Transdermal DNA Vaccine Delivery.
    Bahadoran A; Moeini H; Bejo MH; Hussein MZ; Omar AR
    J Pharm Pharm Sci; 2016; 19(3):325-338. PubMed ID: 27806247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and biophysical characterization of pluronic F127-dendrimer conjugate as a delivery agent of antisense oligonucleotides.
    Dung TH; Kim J; Kim MS; Kim JS; Yoo H
    J Nanosci Nanotechnol; 2008 Oct; 8(10):5326-30. PubMed ID: 19198448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.